The Muslim Times has the best collection of articles for the war against Covid 19, especially about vaccines. Suggested reading by the Muslim Times: FDA authorizes the drug remdesivir for emergency use in COVID-19 patients
Source: BBC
By Richard Galpin
Up to 30% of patients who are seriously ill with coronavirus are developing dangerous blood clots, according to medical experts.
They say the clots, also known as thrombosis, could be contributing to the number of people dying.
Severe inflammation in the lungs – a natural response of the body to the virus – is behind their formation.
Patients worldwide are being affected by many medical complications of the virus, some of which can be fatal.
Back in March, as coronavirus was spreading across the globe, doctors started seeing far higher rates of clots in patients admitted to hospital than they would normally expect.
And there have been other surprises, including the discovery of hundreds of micro-clots in the lungs of some patients.
The virus has also increased cases of deep vein thrombosis – blood clots usually found in the leg – which can be life-threatening when fragments break off and move up the body into the lungs, blocking blood vessels.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
Sorrento Therapeutics and Mount Sinai Health System in New York City have joined forces to develop an antibody cocktail they hope will shield against Covid-19 infection for up to two months. The treatment, called COVI-SHIELD, is designed to be administered as often as necessary, with each dose expected to provide antiviral protection for health care and other essential workers.
If approved by the FDA, it is anticipated that COVI-SHIELD will be offered as a prophylactic for those returning to work and as a therapeutic to those who have been exposed to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes Covid-19. It can also be used for the population at large as a treatment for those who may have been exposed to the disease.
“We’re working with pharma and biotech partners, such as Sorrento, to bring much needed therapies to the clinic,” said Erik Lium, executive vice president and chief commercial innovation officer of the Mount Sinai Health System.
The company is now completing all investigational new drug filing requirements for the triple-antibody combination therapy and expects to commence Phase 1 trials of the drug candidate in the third quarter of 2020. If successful, it would ramp up production so it could produce millions of doses by year-end in its New Jersey and European manufacturing facilities.
Sorrento Therapeutics says that each dose of COVI-SHIELD will deliver a cocktail of three neutralizing antibodies that together would recognize three unique regions of the SARS-CoV-2 Spike protein to ward off the disease.
This therapy is designed to be resistant to future virus mutations and, if approved, should be made available in support of testing, tracing, vaccination and other therapeutic approaches to allow for efficient management of viral infection by protecting those most at risk for up to two months at a time.
https://www.cnbc.com/2020/05/08/sorrento-therapeutics-mount-sinai-develop-covid-19-antibody-shield.html